JP2023082054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023082054A5 JP2023082054A5 JP2023047827A JP2023047827A JP2023082054A5 JP 2023082054 A5 JP2023082054 A5 JP 2023082054A5 JP 2023047827 A JP2023047827 A JP 2023047827A JP 2023047827 A JP2023047827 A JP 2023047827A JP 2023082054 A5 JP2023082054 A5 JP 2023082054A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460118P | 2017-02-17 | 2017-02-17 | |
| US62/460,118 | 2017-02-17 | ||
| PCT/US2018/018557 WO2018152451A1 (en) | 2017-02-17 | 2018-02-17 | Targeted ligand-payload based drug delivery for cell therapy |
| JP2019544016A JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Division JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023082054A JP2023082054A (ja) | 2023-06-13 |
| JP2023082054A5 true JP2023082054A5 (enExample) | 2023-07-19 |
Family
ID=63170493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12343403B2 (enExample) |
| EP (2) | EP3583218B1 (enExample) |
| JP (2) | JP7288402B2 (enExample) |
| KR (1) | KR102595249B1 (enExample) |
| CN (2) | CN118634339B (enExample) |
| AU (1) | AU2018221171B2 (enExample) |
| CA (1) | CA3053534A1 (enExample) |
| ES (1) | ES3024357T3 (enExample) |
| WO (1) | WO2018152451A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US11225520B2 (en) | 2016-02-16 | 2022-01-18 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| CA3053534A1 (en) | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| BR112020014913A2 (pt) * | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| EP3813863A4 (en) | 2018-06-28 | 2022-07-06 | Dana Farber Cancer Institute, Inc. | TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR-T CELLS IN SOLID AND LIQUID MALIGNOS |
| CN112543651B (zh) * | 2018-08-07 | 2023-06-02 | 普渡研究基金会 | 使car t细胞恢复活力 |
| KR20210129058A (ko) * | 2019-01-23 | 2021-10-27 | 더 존스 홉킨스 유니버시티 | 비-면역억제성 fk506 유사체 및 이의 용도 |
| AR119271A1 (es) | 2019-06-11 | 2021-12-09 | Shire Human Genetic Therapies | Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada |
| CA3150095A1 (en) * | 2019-09-06 | 2021-03-11 | Shirley O'dea | IMMUNE CELL ENGINEERING FOR EX VIVO CELLULAR THERAPY APPLICATIONS |
| JP7659550B2 (ja) | 2019-10-23 | 2025-04-09 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 |
| WO2022044024A1 (en) * | 2020-08-31 | 2022-03-03 | Ramot At Tel-Aviv University Ltd. | Small molecule modulators of gsk-3 activity |
| EP4263614A1 (en) | 2020-12-16 | 2023-10-25 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| WO2022140556A1 (en) * | 2020-12-22 | 2022-06-30 | Eutropics Pharmaceuticals, Inc. | Methods and compositions related to bcl2 and bim heterodimer antibodies |
| CN113462649B (zh) * | 2021-05-27 | 2022-08-23 | 浙江大学 | Mek抑制剂在减少car-t细胞耗竭和终末分化中的应用 |
| US20250084175A1 (en) * | 2021-07-21 | 2025-03-13 | Immunitybio, Inc. | GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS |
| CN116041545A (zh) * | 2022-12-12 | 2023-05-02 | 南方医科大学 | 一种靶向荧光素或生物素的通用型car及其应用 |
| WO2024206913A2 (en) * | 2023-03-31 | 2024-10-03 | Northwestern University | Compositions for antigen-specific immune cell activation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| PT2371854E (pt) | 2001-03-09 | 2014-08-25 | Jackson H M Found Military Med | Indução da imunidade tumoral por variantes da proteína de ligação ao folato |
| EP1748070A4 (en) * | 2004-04-26 | 2007-07-18 | Takami Matsuyama | THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA) |
| WO2011079227A1 (en) * | 2009-12-23 | 2011-06-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CA2757897A1 (en) | 2009-04-08 | 2010-10-14 | Anna M. Wu | Human protein scaffold with controlled serum pharmacokinetics |
| WO2016098078A2 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
| WO2016164745A1 (en) | 2015-04-10 | 2016-10-13 | The Methodist Hospital System | Cd117 ligand-drug conjugates for targeted cancer therapy |
| US11034752B2 (en) * | 2015-08-12 | 2021-06-15 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| TW201740958A (zh) * | 2016-01-15 | 2017-12-01 | 依圖比克斯公司 | 用於t細胞免疫療法之方法及組合物 |
| US11174306B2 (en) * | 2016-10-19 | 2021-11-16 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| SG11201903454VA (en) * | 2016-11-02 | 2019-05-30 | Univ Basel | Immunologically discernible cell surface variants for use in cell therapy |
| CA3053534A1 (en) | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
-
2018
- 2018-02-17 CA CA3053534A patent/CA3053534A1/en active Pending
- 2018-02-17 EP EP18754879.7A patent/EP3583218B1/en active Active
- 2018-02-17 ES ES18754879T patent/ES3024357T3/es active Active
- 2018-02-17 US US16/486,632 patent/US12343403B2/en active Active
- 2018-02-17 JP JP2019544016A patent/JP7288402B2/ja active Active
- 2018-02-17 WO PCT/US2018/018557 patent/WO2018152451A1/en not_active Ceased
- 2018-02-17 CN CN202410423409.8A patent/CN118634339B/zh active Active
- 2018-02-17 KR KR1020197026818A patent/KR102595249B1/ko active Active
- 2018-02-17 AU AU2018221171A patent/AU2018221171B2/en active Active
- 2018-02-17 EP EP25163099.2A patent/EP4600267A3/en active Pending
- 2018-02-17 CN CN201880024308.6A patent/CN110662839A/zh active Pending
-
2023
- 2023-03-24 JP JP2023047827A patent/JP2023082054A/ja active Pending
-
2025
- 2025-04-30 US US19/194,112 patent/US20250262313A1/en active Pending